Arch Biopartners
ON - TorontoBiotechnology
Focus: Arch Biopartners is a Toronto-based biotech company focused on antibodies, peptides, and small molecules for infectious diseases and nephrology. As a publicly-listed company founded in 2015, it operates at the early clinical stage with a focused pipeline.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
6
Should You Work at Arch Biopartners?
AI assessmentBest suited for scientists and R&D specialists seeking meaningful impact at an early-stage public biotech; unsuitable for those prioritizing job security, company scale, or established career pathways.
Why Work Here
- Focused therapeutic areas (infectious diseases and nephrology) reduce market noise and enable deep expertise building
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
LSALT peptide
Acute Kidney InjuryClinical Trials (3)
NCT04402957LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
Phase 2Help build intelligence for Arch Biopartners
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.